Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Moodys
Baxter
Johnson and Johnson
Harvard Business School

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GLUCAGEN

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Glucagen

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00745186 ↗ Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers Completed Hospira, Inc. Phase 1 2007-08-01 The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamic bioequivalence and safety of Hospira Glucagon for Injection and GlucaGen® in healthy volunteers.
NCT00745186 ↗ Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers Completed Hospira, now a wholly owned subsidiary of Pfizer Phase 1 2007-08-01 The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamic bioequivalence and safety of Hospira Glucagon for Injection and GlucaGen® in healthy volunteers.
NCT00747968 ↗ The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET Completed Aarhus University Hospital Phase 2/Phase 3 2010-02-01 30 type 2 diabetic patients will be PET-scanned twice ( half of the patients heart-PET, half of the patients CNS-PET) in random order with infusions of placebo or GLP-1-analogue during hyperglycemic clamp to uncover the metabolic effects of GLP-1-analogues in perspectives of intervention of macrovascular late diabetic pathology such as stroke and AMI. Earlier studies have revealed tendencies towards steady glucose metabolism in the CNS despite fluctuations in blood sugar when infusing native GLP-1.
NCT00747968 ↗ The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET Completed Eli Lilly and Company Phase 2/Phase 3 2010-02-01 30 type 2 diabetic patients will be PET-scanned twice ( half of the patients heart-PET, half of the patients CNS-PET) in random order with infusions of placebo or GLP-1-analogue during hyperglycemic clamp to uncover the metabolic effects of GLP-1-analogues in perspectives of intervention of macrovascular late diabetic pathology such as stroke and AMI. Earlier studies have revealed tendencies towards steady glucose metabolism in the CNS despite fluctuations in blood sugar when infusing native GLP-1.
NCT00747968 ↗ The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET Completed University of Aarhus Phase 2/Phase 3 2010-02-01 30 type 2 diabetic patients will be PET-scanned twice ( half of the patients heart-PET, half of the patients CNS-PET) in random order with infusions of placebo or GLP-1-analogue during hyperglycemic clamp to uncover the metabolic effects of GLP-1-analogues in perspectives of intervention of macrovascular late diabetic pathology such as stroke and AMI. Earlier studies have revealed tendencies towards steady glucose metabolism in the CNS despite fluctuations in blood sugar when infusing native GLP-1.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Glucagen

Condition Name

Condition Name for Glucagen
Intervention Trials
Hypoglycemia 11
Diabetes Mellitus, Type 1 6
Type 1 Diabetes 4
Type 1 Diabetes Mellitus 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Glucagen
Intervention Trials
Diabetes Mellitus 16
Diabetes Mellitus, Type 1 15
Hypoglycemia 14
Diabetes Mellitus, Type 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Glucagen

Trials by Country

Trials by Country for Glucagen
Location Trials
United States 31
Denmark 8
Germany 8
Canada 4
Austria 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Glucagen
Location Trials
Oregon 5
California 3
Minnesota 3
Indiana 3
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Glucagen

Clinical Trial Phase

Clinical Trial Phase for Glucagen
Clinical Trial Phase Trials
Phase 4 3
Phase 3 5
Phase 2/Phase 3 3
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Glucagen
Clinical Trial Phase Trials
Completed 22
Recruiting 4
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Glucagen

Sponsor Name

Sponsor Name for Glucagen
Sponsor Trials
Steno Diabetes Center Copenhagen 5
Eli Lilly and Company 5
Zealand Pharma 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Glucagen
Sponsor Trials
Other 34
Industry 22
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
McKesson
Merck
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.